Ovarian Cancer Global Clinical Trials Review, H1, 2018

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500

GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Sarah Cannon Research Institute LLC
Merck & Co Inc
Sanofi
GlaxoSmithKline Plc
Pfizer Inc
Novartis AG
Eli Lilly and Co
Bristol-Myers Squibb Co

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Report Guidance 7

GlobalData Clinical Trials Report Coverage 8

Clinical Trials by Region 9

Clinical Trials and Average Enrollment by Country 10

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13

Top Five Countries Contributing to Clinical Trials in Europe 14

Top Countries Contributing to Clinical Trials in North America 15

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16

Top Five Countries Contributing to Clinical Trials in Central and South America 17

Clinical Trials by G7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 18

Clinical Trials by Phase in G7 Countries 20

Clinical Trials in G7 Countries by Trial Status 21

Clinical Trials by E7 Countries: Proportion of Ovarian Cancer to Oncology Clinical Trials 23

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 28

Clinical Trials by Trial Status 29

Clinical Trials by End Point Status 31

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 33

Prominent Sponsors 34

Top Companies Participating in Ovarian Cancer Therapeutics Clinical Trials 36

Prominent Drugs 38

Latest Clinical Trials News on Ovarian Cancer 39

Apr 24, 2018: TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA 39

Apr 17, 2018: Sareum Notes that Sierra Oncology will Present Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARP Inhibitors at the AACR 2018 Annual Meeting 39

Apr 16, 2018: BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting 40

Apr 16, 2018: Preclinical Data Presented at AACR 2018 Shows Esperance Pharmaceuticals EP-100 Is Synergistic with PARP Inhibitor Olaparib in Ovarian Cancer 41

Apr 16, 2018: Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting 41

Apr 16, 2018: Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research 42

Apr 16, 2018: Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer 43

Apr 13, 2018: Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018 43

Apr 13, 2018: TyrNovo to Present at 2018 Annual Meeting of the American Association for Cancer Research 44

Apr 12, 2018: TCR2 Therapeutics to Present New Preclinical Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting 44

Apr 11, 2018: Tarveda Therapeutics to Present Preclinical Data on PEN-866 in Combination with PARP Inhibitors at the 2018 AACR Annual Meeting 44

Apr 09, 2018: Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting 45

Apr 05, 2018: First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer 45

Mar 29, 2018: Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 45

Mar 28, 2018: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150 46

Mar 26, 2018: Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer 46

Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting 47

Mar 16, 2018: “Recombinant ANTI-EpCAM And ANTI-CD3 Human-Mouse Chimeric Bispecific Antibody For Injection” Was Granted Drug Clinical Trial Approval 48

Mar 15, 2018: TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research 48

Mar 15, 2018: Phase 1 Clinical Data With Cyclacel's CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting 49

Mar 15, 2018: ArQule to Present Data on miransertib at the 2018 American Association for Cancer Research (AACR) Annual Meeting 49

Mar 15, 2018: MabVax Therapeutics to present results from preclinical work on anti-cancer drug 49

Mar 14, 2018: Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting 50

Mar 14, 2018: Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting 50

Mar 08, 2018: TyrNovo to Present at BIO-Europe Spring 2018 Conference 51

Feb 22, 2018: Europe Approves JHL Biotech’s Clinical Trial Application for Bevacizumab Biosimilar to Affordably Treat Colorectal, Lung, and Ovarian Cancers 51

Feb 08, 2018: Innovation Pharmaceuticals Concludes Successful Phase 2a Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed 51

Feb 07, 2018: GamaMabs Pharma receives Orphan Drug Designation from the US FDA for lead compound GM102 52

Jan 31, 2018: Oncoinvent: New Radspherin data published 52

Jan 31, 2018: Oncolix Sponsors Additional Research with MD Anderson Cancer Center 52

Clinical Trial Profile Snapshots 53

Appendix 1833

Abbreviations 1833

Definitions 1833

Research Methodology 1834

Secondary Research 1834

About GlobalData 1835

Contact Us 1835

Disclaimer 1835

Source 1836

Table

Ovarian Cancer Therapeutics, Global, Clinical Trials by Region, 2018* 9

Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10

Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 12

Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 13

Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 14

Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries, 2018* 15

Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 16

Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 17

Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 18

Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 20

Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 21

Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 23

Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase, 2018* 27

Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 28

Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31

Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32

Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 33

Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

Figures

Ovarian Cancer Therapeutics, Global, Clinical Trials by Region (%), 2018* 9

Ovarian Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 10

Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 12

Ovarian Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 13

Ovarian Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 14

Ovarian Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 15

Ovarian Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 16

Ovarian Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 17

Proportion of Ovarian Cancer to Oncology Clinical Trials, G7 Countries (%), 2018* 18

Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 20

Ovarian Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 21

Proportion of Ovarian Cancer to Oncology Clinical Trials, E7 Countries (%), 2018* 23

Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 24

Ovarian Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Ovarian Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2018* 27

Ovarian Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 28

Ovarian Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Ovarian Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2018* 31

Ovarian Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 32

Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 33

Ovarian Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Ovarian Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Ovarian Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

GlobalData Methodology 1834

Frequently asked questions

Ovarian Cancer Global Clinical Trials Review, H1, 2018 thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ovarian Cancer Global Clinical Trials Review, H1, 2018 in real time.

  • Access a live Ovarian Cancer Global Clinical Trials Review, H1, 2018 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.